DXCM Dexcom Loading...

From ABT earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
13:00
Jul 16 ◎
Robert Ford CEO, Abbott Laboratories ABT Q2 FY26 call
U.S. Type-2 CGM reimbursement could land in the fall, unlocking roughly 10 million Medicare beneficiaries and a multi-billion dollar opportunity; Abbott is pre-positioning sales force and distribution. — A CGM reimbursement expansion at CMS would enlarge the addressable market for both Abbott and Dexcom, with meaningful timing-driven sales upside.
DXCM
MED

About DXCM Analyst Coverage

Buzzberg tracks DXCM (Dexcom) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Robert Ford.